Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Peptide Analogs
A synthetic six-residue peptide bearing a non-canonical D-2-methyltryptophan substitution and a C-terminal amide.
Reviewed by Dr. James Whitfield, PharmD · Published · Last reviewed · For research use only.
Type
Synthetic peptide (hexapeptide)
Molecular formula
C47H58N12O6
Molecular weight
887.04 g/mol
CAS number
140703-51-1
Amino acids
6
Sequence
His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2
Modification
D-2-methyltryptophan; D-Phe; C-terminal amide.
A synthetic peptidyl hexapeptide of the GHRP series that engages two structurally distinct membrane-protein binding partners. The first is a class A G-protein-coupled receptor characterized in binding and photoaffinity-labeling studies of brain and pituitary membranes. The second is CD36, a heavily glycosylated class B membrane glycoprotein of roughly 472 residues, identified through photoaffinity cross-linking as a binding partner whose contact interface maps to a lysine-rich extracellular segment (residues Gln155-Lys183). The molecule's defining structural feature is substitution of the position-2 tryptophan of the parent GHRP-6 sequence with D-2-methyl-tryptophan, a non-canonical residue that confers conformational rigidity and resistance to proteolytic degradation; a conserved core and a turn-stabilized backbone are recurring pharmacophore elements across the GHRP series.
Lyophilized
20°C
typically stable 24-36 months desiccated.
Avoid freeze-thaw; aliquot; protect from light and moisture.
Reviews
Ishida J, et al. (2020). JCSM Rapid Communications
Proulx C, et al. (2020). Biomedicines
Mao Y, et al. (2014). J Geriatr Cardiol
Reviews
Demers A, et al. (2008). PPAR Research
Clinical
Arvat E, et al. (1997). Peptides
Arvat E, et al. (1997). Eur J Endocrinol
Ghigo E, et al. (1994). J Clin Endocrinol Metab
Imbimbo BP, et al. (1994). Eur J Clin Pharmacol
Primary research
McDonald H, et al. (2020). Biomed Pharmacother
Cheng XL, et al. (2019). Peptides
McDonald H, et al. (2018). Physiol Rep
Mao Y, et al. (2013). Endocrinology
Proulx C, et al. (2012). J Med Chem
Sabatino D, et al. (2011). J Am Chem Soc
Demers A, et al. (2004). Biochem J
Bodart V, et al. (2002). Circ Res
Tivesten Å, et al. (2000). Endocrinology
Locatelli V, et al. (1999). Endocrinology
Bodart V, et al. (1999). Circ Res
Muccioli G, et al. (1998). J Endocrinol
Torsello A, et al. (1996). Neuroendocrinology
Deghenghi R, et al. (1994). Life Sci
Research Use Only
These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.
| Compound | Type | Molecular weight | CAS number |
|---|---|---|---|
| HexarelinThis page | Synthetic peptide (hexapeptide) | 887.04 g/mol | 140703-51-1 |
| LUV RT | Synthetic peptide (acylated, 39 residues) | ~4,731 Da | 2381089-83-2 |
| LUV SM | Synthetic peptide (acylated, 31 residues) | ~4,114 g/mol | 910463-68-2 |
| LUV TRZ2 | Synthetic linear peptide (acylated, 39 residues) | ~4,814 g/mol | 2023788-19-2 |
| AOD-9604 | Synthetic peptide (cyclic, 16 residues) | ~1,815 g/mol | 221231-10-3 |
Comparison of laboratory reference specifications only. For research use only; not a therapeutic comparison.
Quality & methods